WO2016034137A1 - 吡唑并[3,4-c]吡啶类衍生物 - Google Patents
吡唑并[3,4-c]吡啶类衍生物 Download PDFInfo
- Publication number
- WO2016034137A1 WO2016034137A1 PCT/CN2015/088898 CN2015088898W WO2016034137A1 WO 2016034137 A1 WO2016034137 A1 WO 2016034137A1 CN 2015088898 W CN2015088898 W CN 2015088898W WO 2016034137 A1 WO2016034137 A1 WO 2016034137A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- resulting mixture
- mmol
- oxo
- pyridine
- added
- Prior art date
Links
- 150000005231 pyrazolo[3,4-c]pyridines Chemical class 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 227
- 150000001875 compounds Chemical class 0.000 claims abstract description 139
- 230000003287 optical effect Effects 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 20
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 19
- 208000034158 bleeding Diseases 0.000 claims abstract description 19
- 230000000740 bleeding effect Effects 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 230000008092 positive effect Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000004429 atom Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 206010047249 Venous thrombosis Diseases 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 108010074860 Factor Xa Proteins 0.000 claims description 10
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 6
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 208000005189 Embolism Diseases 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 208000001435 Thromboembolism Diseases 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 210000004351 coronary vessel Anatomy 0.000 claims description 5
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 230000001052 transient effect Effects 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 238000005576 amination reaction Methods 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 208000021328 arterial occlusion Diseases 0.000 claims 2
- FDWPTIRISHPJMZ-UHFFFAOYSA-N 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperazin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CNCC3)=O)=C2C(C(N)=O)=N1 FDWPTIRISHPJMZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 578
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 352
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 180
- 238000006243 chemical reaction Methods 0.000 description 175
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 151
- 235000019439 ethyl acetate Nutrition 0.000 description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 121
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 93
- 239000012074 organic phase Substances 0.000 description 87
- 230000002829 reductive effect Effects 0.000 description 87
- 239000007787 solid Substances 0.000 description 87
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- -1 1,2-ethylene, 1,3 - propylene, 1,4-butylene Chemical group 0.000 description 59
- 238000010898 silica gel chromatography Methods 0.000 description 56
- 239000013058 crude material Substances 0.000 description 52
- 239000012043 crude product Substances 0.000 description 49
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 43
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 40
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 34
- 239000012299 nitrogen atmosphere Substances 0.000 description 31
- 239000000047 product Substances 0.000 description 31
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 30
- 239000005457 ice water Substances 0.000 description 30
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 28
- 239000004698 Polyethylene Substances 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 24
- 229910000027 potassium carbonate Inorganic materials 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 20
- 239000008346 aqueous phase Substances 0.000 description 17
- 235000010288 sodium nitrite Nutrition 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 15
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 14
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 14
- 238000002953 preparative HPLC Methods 0.000 description 14
- 239000001632 sodium acetate Substances 0.000 description 14
- 235000017281 sodium acetate Nutrition 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000008213 purified water Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- SRICXDSOENVWEU-UHFFFAOYSA-N 5-morpholin-4-yl-2,3-dihydro-1h-pyridin-6-one Chemical compound O=C1NCCC=C1N1CCOCC1 SRICXDSOENVWEU-UHFFFAOYSA-N 0.000 description 8
- 230000002785 anti-thrombosis Effects 0.000 description 8
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 7
- 108010014173 Factor X Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 6
- 229960005080 warfarin Drugs 0.000 description 6
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 6
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 5
- MDCPVYOIYISUFL-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1h-pyridin-6-one Chemical compound ClC1=CCCNC1=O MDCPVYOIYISUFL-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 210000001168 carotid artery common Anatomy 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 5
- YPZLQVWKOHWDMZ-UHFFFAOYSA-N ethyl 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound C1NCCC2=C1NN=C2C(=O)OCC YPZLQVWKOHWDMZ-UHFFFAOYSA-N 0.000 description 5
- VNDGHBFEIPEUBT-UHFFFAOYSA-N ethyl 7-oxo-2,4,5,6-tetrahydropyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound C1CNC(=O)C=2C1=C(C(=O)OCC)NN=2 VNDGHBFEIPEUBT-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- MXZYLIAPYSJTEK-UHFFFAOYSA-N 1-(4-methoxyphenyl)-7-oxo-5,6-dihydro-4h-pyrazolo[3,4-c]pyridine-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)NCC2)=C2C(C(O)=O)=N1 MXZYLIAPYSJTEK-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 229960003886 apixaban Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- PSOYDCQSXGQZKM-UHFFFAOYSA-N ethyl 1-(4-methoxyphenyl)-7-oxo-5,6-dihydro-4h-pyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound C1CNC(=O)C2=C1C(C(=O)OCC)=NN2C1=CC=C(OC)C=C1 PSOYDCQSXGQZKM-UHFFFAOYSA-N 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WHDKRPSSEZGGMR-UHFFFAOYSA-N 1-(4-iodophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(I)C=C1 WHDKRPSSEZGGMR-UHFFFAOYSA-N 0.000 description 3
- XFFILAFLGDUMBF-UHFFFAOYSA-N 2-phenoxyacetaldehyde Chemical compound O=CCOC1=CC=CC=C1 XFFILAFLGDUMBF-UHFFFAOYSA-N 0.000 description 3
- RDVZKTUYZCMKJY-UHFFFAOYSA-N 3,3-dichloropiperidin-2-one Chemical compound ClC1(Cl)CCCNC1=O RDVZKTUYZCMKJY-UHFFFAOYSA-N 0.000 description 3
- FDWHMIVBLKBTFC-UHFFFAOYSA-N 3-bromo-n-(2-phenoxyethyl)aniline Chemical compound BrC1=CC=CC(NCCOC=2C=CC=CC=2)=C1 FDWHMIVBLKBTFC-UHFFFAOYSA-N 0.000 description 3
- HEROFNJKFRAPQN-UHFFFAOYSA-N 3-bromo-n-[(2-methylpyrazol-3-yl)methyl]aniline Chemical compound CN1N=CC=C1CNC1=CC=CC(Br)=C1 HEROFNJKFRAPQN-UHFFFAOYSA-N 0.000 description 3
- ASLWQZGYKULGPD-UHFFFAOYSA-N 4-ethoxy-3-fluoroaniline Chemical compound CCOC1=CC=C(N)C=C1F ASLWQZGYKULGPD-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- INDKQWGBXGVQEV-UHFFFAOYSA-N BrC1=CC(=C(C=C1)N(C(OC(C)(C)C)=O)CCOC)F Chemical compound BrC1=CC(=C(C=C1)N(C(OC(C)(C)C)=O)CCOC)F INDKQWGBXGVQEV-UHFFFAOYSA-N 0.000 description 3
- NXLSWJPLDWJBAO-UHFFFAOYSA-N C(C)NC=1C=C(C=CC=1OCCC)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O Chemical compound C(C)NC=1C=C(C=CC=1OCCC)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O NXLSWJPLDWJBAO-UHFFFAOYSA-N 0.000 description 3
- ZZHWKLGFHUTIDE-UHFFFAOYSA-N CN(CCCN(C(OC(C)(C)C)=O)C1=CC=C(C=C1)I)C Chemical compound CN(CCCN(C(OC(C)(C)C)=O)C1=CC=C(C=C1)I)C ZZHWKLGFHUTIDE-UHFFFAOYSA-N 0.000 description 3
- DXLTUBHMGCYBDV-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(C(=CC=C1)C)=O)=O)C(=O)OCC Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(C(=CC=C1)C)=O)=O)C(=O)OCC DXLTUBHMGCYBDV-UHFFFAOYSA-N 0.000 description 3
- OUZSNHCRCTXENT-UHFFFAOYSA-N IC1=CC(=C(C=C1)NC(CCCNC(OC(C)(C)C)=O)=O)C Chemical compound IC1=CC(=C(C=C1)NC(CCCNC(OC(C)(C)C)=O)=O)C OUZSNHCRCTXENT-UHFFFAOYSA-N 0.000 description 3
- AQSSRTPAUANBOA-UHFFFAOYSA-N IC1=CC=C(C=C1)N(C(C(C)C)=O)C Chemical compound IC1=CC=C(C=C1)N(C(C(C)C)=O)C AQSSRTPAUANBOA-UHFFFAOYSA-N 0.000 description 3
- JSCAFNYFWKNJLB-UHFFFAOYSA-N IC1=CC=C(OCCCN(C(OC(C)(C)C)=O)C)C=C1 Chemical compound IC1=CC=C(OCCCN(C(OC(C)(C)C)=O)C)C=C1 JSCAFNYFWKNJLB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- PCJBVBFDDZLXCP-UHFFFAOYSA-N O=C1N(C(CC1)=O)C1=CC=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O Chemical compound O=C1N(C(CC1)=O)C1=CC=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O PCJBVBFDDZLXCP-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- MZPYRLHUTZAOMB-UHFFFAOYSA-N n-ethyl-5-iodo-2-propoxyaniline Chemical compound CCCOC1=CC=C(I)C=C1NCC MZPYRLHUTZAOMB-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- STWNGMSGPBZFMX-UHFFFAOYSA-N pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 STWNGMSGPBZFMX-UHFFFAOYSA-N 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- KSIBFNLXLWQOOB-UHFFFAOYSA-N tert-butyl 4-(4-bromo-2-methoxyphenyl)piperazine-1-carboxylate Chemical compound COC1=CC(Br)=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 KSIBFNLXLWQOOB-UHFFFAOYSA-N 0.000 description 3
- ZKUUAUDQEMLNHQ-UHFFFAOYSA-N tert-butyl 4-[2-(3-bromophenyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCC1=CC=CC(Br)=C1 ZKUUAUDQEMLNHQ-UHFFFAOYSA-N 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- CFZRRGPCDUOJHX-UHFFFAOYSA-N 1-(4-iodophenyl)piperazine Chemical compound C1=CC(I)=CC=C1N1CCNCC1 CFZRRGPCDUOJHX-UHFFFAOYSA-N 0.000 description 2
- IUSWJCWFXRTVCM-UHFFFAOYSA-N 1-(4-iodophenyl)pyrrolidin-2-one Chemical compound C1=CC(I)=CC=C1N1C(=O)CCC1 IUSWJCWFXRTVCM-UHFFFAOYSA-N 0.000 description 2
- LUIIVYXZQHQSEH-UHFFFAOYSA-N 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxoazepan-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(CCCCC1)=O)=O)C(=O)N LUIIVYXZQHQSEH-UHFFFAOYSA-N 0.000 description 2
- XOAWHQBWIYBHCF-UHFFFAOYSA-N 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopyrrolidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(CCC1)=O)=O)C(=O)N XOAWHQBWIYBHCF-UHFFFAOYSA-N 0.000 description 2
- NDYXXQCMSLZHLC-UHFFFAOYSA-N 1-ethoxy-2-fluoro-4-nitrobenzene Chemical compound CCOC1=CC=C([N+]([O-])=O)C=C1F NDYXXQCMSLZHLC-UHFFFAOYSA-N 0.000 description 2
- JREJQAWGQCMSIY-UHFFFAOYSA-N 1-methyl-pyrazole-5-carboxylic acid Chemical compound CN1N=CC=C1C(O)=O JREJQAWGQCMSIY-UHFFFAOYSA-N 0.000 description 2
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 2
- DFKQZCVLSJIRES-UHFFFAOYSA-N 2-(3-bromophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=CC(Br)=C1 DFKQZCVLSJIRES-UHFFFAOYSA-N 0.000 description 2
- YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- JBZBRGJVPVQYJG-UHFFFAOYSA-N 3-(ethoxymethyl)aniline Chemical compound CCOCC1=CC=CC(N)=C1 JBZBRGJVPVQYJG-UHFFFAOYSA-N 0.000 description 2
- KRGXWTOLFOPIKV-UHFFFAOYSA-N 3-(methylamino)propan-1-ol Chemical compound CNCCCO KRGXWTOLFOPIKV-UHFFFAOYSA-N 0.000 description 2
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 2
- GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 2
- RHWDEIXKHGCDOG-UHFFFAOYSA-N 4-iodo-2-nitrophenol Chemical compound OC1=CC=C(I)C=C1[N+]([O-])=O RHWDEIXKHGCDOG-UHFFFAOYSA-N 0.000 description 2
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 2
- VSWIVELJJRLAQF-UHFFFAOYSA-N 5-(4-bromo-2-chlorophenoxy)pentan-2-one Chemical compound CC(=O)CCCOC1=CC=C(Br)C=C1Cl VSWIVELJJRLAQF-UHFFFAOYSA-N 0.000 description 2
- CZGQFBNTABQTMB-UHFFFAOYSA-N 5-iodo-2-propoxyaniline Chemical compound CCCOC1=CC=C(I)C=C1N CZGQFBNTABQTMB-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- UUISCRAGFNILKA-UHFFFAOYSA-N BrC1=CC(=C(C(=O)N2CCN(CC2)C(=O)OC(C)(C)C)C=C1)C Chemical compound BrC1=CC(=C(C(=O)N2CCN(CC2)C(=O)OC(C)(C)C)C=C1)C UUISCRAGFNILKA-UHFFFAOYSA-N 0.000 description 2
- XTGOYLNVTZHPMD-UHFFFAOYSA-N C(C)OCC=1C=C(C=CC=1)N1N=C(C2=C1C(NCC2)=O)C(=O)OCC Chemical compound C(C)OCC=1C=C(C=CC=1)N1N=C(C2=C1C(NCC2)=O)C(=O)OCC XTGOYLNVTZHPMD-UHFFFAOYSA-N 0.000 description 2
- BCSIHPOEJHMJFA-UHFFFAOYSA-N C(N)(=O)C1=NN(C=2C(N(CCC=21)C1=CC(=C(C(=O)N2CCN(CC2)C(=O)OC(C)(C)C)C=C1)C)=O)C1=CC=C(C=C1)OC Chemical compound C(N)(=O)C1=NN(C=2C(N(CCC=21)C1=CC(=C(C(=O)N2CCN(CC2)C(=O)OC(C)(C)C)C=C1)C)=O)C1=CC=C(C=C1)OC BCSIHPOEJHMJFA-UHFFFAOYSA-N 0.000 description 2
- VOMGUCWOHHYSEW-UHFFFAOYSA-N C(N)(=O)C1=NN(C=2C(N(CCC=21)C1=CC=C(C=C1)N(C(OC(C)(C)C)=O)CCCN(C)C)=O)C1=CC=C(C=C1)OC Chemical compound C(N)(=O)C1=NN(C=2C(N(CCC=21)C1=CC=C(C=C1)N(C(OC(C)(C)C)=O)CCCN(C)C)=O)C1=CC=C(C=C1)OC VOMGUCWOHHYSEW-UHFFFAOYSA-N 0.000 description 2
- 0 C*NC(CCC(N)=O)=O Chemical compound C*NC(CCC(N)=O)=O 0.000 description 2
- DNHNXHIZUWURFD-UHFFFAOYSA-N CN(CCCNC1=CC=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O)C Chemical compound CN(CCCNC1=CC=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O)C DNHNXHIZUWURFD-UHFFFAOYSA-N 0.000 description 2
- CFVKHFJDQUBQGK-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC(=CC=C1)CCN1CCNCC1)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC(=CC=C1)CCN1CCNCC1)=O)C(=O)N CFVKHFJDQUBQGK-UHFFFAOYSA-N 0.000 description 2
- PIIOPWVRVPYQSP-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N(C(C(C)C)=O)C)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N(C(C(C)C)=O)C)=O)C(=O)N PIIOPWVRVPYQSP-UHFFFAOYSA-N 0.000 description 2
- FFFOKEWKEYRMCN-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(C(=CC=C1)C)=O)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(C(=CC=C1)C)=O)=O)C(=O)N FFFOKEWKEYRMCN-UHFFFAOYSA-N 0.000 description 2
- RPNUDJMXFDGFLX-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1CCN(CC1)C)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1CCN(CC1)C)=O)C(=O)N RPNUDJMXFDGFLX-UHFFFAOYSA-N 0.000 description 2
- NSHRJNLEAWWRHT-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)NCCNC)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)NCCNC)=O)C(=O)N NSHRJNLEAWWRHT-UHFFFAOYSA-N 0.000 description 2
- ZJSSMUGUYAEQNW-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)OCCCNC)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)OCCCNC)=O)C(=O)N ZJSSMUGUYAEQNW-UHFFFAOYSA-N 0.000 description 2
- KDSDUGKHZCRMSQ-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)CCCCN1CCCCC1)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)CCCCN1CCCCC1)=O)C(=O)N KDSDUGKHZCRMSQ-UHFFFAOYSA-N 0.000 description 2
- CZASJDKSPKRTAN-UHFFFAOYSA-N COC=1C=C(C=CC=1CN1CCNCC1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O Chemical compound COC=1C=C(C=CC=1CN1CCNCC1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O CZASJDKSPKRTAN-UHFFFAOYSA-N 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AWLBAPQBNNZJDC-UHFFFAOYSA-N ClC=1C=C(C=CC=1OCCCC(C)=O)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O Chemical compound ClC=1C=C(C=CC=1OCCCC(C)=O)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O AWLBAPQBNNZJDC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VFJAEGOOOXGTJP-UHFFFAOYSA-N FC=1C=C(C=CC=1NCCOC)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O Chemical compound FC=1C=C(C=CC=1NCCOC)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O VFJAEGOOOXGTJP-UHFFFAOYSA-N 0.000 description 2
- XTDDBOHDSNECSU-UHFFFAOYSA-N FC=1C=C(C=CC=1OC)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(COCC1)=O)=O)C(=O)N Chemical compound FC=1C=C(C=CC=1OC)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(COCC1)=O)=O)C(=O)N XTDDBOHDSNECSU-UHFFFAOYSA-N 0.000 description 2
- MWRQDGGSKMIMLH-UHFFFAOYSA-N FC=1C=C(C=CC=1OC)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(COCC1)=O)=O)C(=O)OCC Chemical compound FC=1C=C(C=CC=1OC)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(COCC1)=O)=O)C(=O)OCC MWRQDGGSKMIMLH-UHFFFAOYSA-N 0.000 description 2
- RRSMISZBUCHUPW-UHFFFAOYSA-N FC=1C=C(C=CC=1OC)NNC(C(=O)OCC)Cl Chemical compound FC=1C=C(C=CC=1OC)NNC(C(=O)OCC)Cl RRSMISZBUCHUPW-UHFFFAOYSA-N 0.000 description 2
- 229940122564 Factor X inhibitor Drugs 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WTFLGOWRBBJGSP-UHFFFAOYSA-N IC1=CC(=C(C=C1)OCCC)[N+](=O)[O-] Chemical compound IC1=CC(=C(C=C1)OCCC)[N+](=O)[O-] WTFLGOWRBBJGSP-UHFFFAOYSA-N 0.000 description 2
- XCBORCBGGPWCMI-UHFFFAOYSA-N IC1=CC=C(C=C1)NCCN(C(OC(C)(C)C)=O)C Chemical compound IC1=CC=C(C=C1)NCCN(C(OC(C)(C)C)=O)C XCBORCBGGPWCMI-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- XRURWBKRKZLENR-UHFFFAOYSA-N azane;ethane-1,2-diol Chemical compound N.OCCO XRURWBKRKZLENR-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ADSMMLJMHOZURY-UHFFFAOYSA-N ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxoazepan-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(CCCCC1)=O)=O)C(=O)OCC ADSMMLJMHOZURY-UHFFFAOYSA-N 0.000 description 2
- UPUYQULPNPBUMU-UHFFFAOYSA-N ethyl 2,3,3a,4-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound C(C)OC(=O)C1NNC2=CN=CCC21 UPUYQULPNPBUMU-UHFFFAOYSA-N 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- RKLZFBRHHHSATP-UHFFFAOYSA-N n-(3-bromophenyl)-2-methylpyrazole-3-carboxamide Chemical compound CN1N=CC=C1C(=O)NC1=CC=CC(Br)=C1 RKLZFBRHHHSATP-UHFFFAOYSA-N 0.000 description 2
- KZLMXQOVEPPAEE-UHFFFAOYSA-N n-(4-iodophenyl)-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=C(I)C=C1 KZLMXQOVEPPAEE-UHFFFAOYSA-N 0.000 description 2
- ZPJHYCJWBVKEEF-UHFFFAOYSA-N n-[(3-bromophenyl)methyl]-3-imidazol-1-ylpropan-1-amine Chemical compound BrC1=CC=CC(CNCCCN2C=NC=C2)=C1 ZPJHYCJWBVKEEF-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229960001148 rivaroxaban Drugs 0.000 description 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- XJWSXVLTAHLQBZ-UHFFFAOYSA-N tert-butyl 4-(4-bromo-2-hydroxybenzoyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC=C(Br)C=C1O XJWSXVLTAHLQBZ-UHFFFAOYSA-N 0.000 description 2
- OWZLFZBBCCXARQ-UHFFFAOYSA-N tert-butyl 4-(4-bromo-2-methoxybenzoyl)piperazine-1-carboxylate Chemical compound COC1=CC(Br)=CC=C1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1 OWZLFZBBCCXARQ-UHFFFAOYSA-N 0.000 description 2
- PIICWMWIUZRPIZ-UHFFFAOYSA-N tert-butyl 4-[2-(3-bromophenyl)acetyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)CC1=CC=CC(Br)=C1 PIICWMWIUZRPIZ-UHFFFAOYSA-N 0.000 description 2
- GJGLBUZZTLPCOT-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)-n-methylcarbamate Chemical compound OCCCN(C)C(=O)OC(C)(C)C GJGLBUZZTLPCOT-UHFFFAOYSA-N 0.000 description 2
- DMHILFAMOKMHSO-UHFFFAOYSA-N tert-butyl n-(4-bromo-2-fluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(Br)C=C1F DMHILFAMOKMHSO-UHFFFAOYSA-N 0.000 description 2
- CGALRQWBJFDAKN-UHFFFAOYSA-N tert-butyl n-(4-iodophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(I)C=C1 CGALRQWBJFDAKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- QUPXJEZOJHCQCP-UHFFFAOYSA-N 1-(3-fluoro-4-methoxyphenyl)-7-oxo-6-[4-(2-oxopyrrolidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide Chemical compound FC=1C=C(C=CC=1OC)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(CCC1)=O)=O)C(=O)N QUPXJEZOJHCQCP-UHFFFAOYSA-N 0.000 description 1
- OYDSTJMVOOOYDW-UHFFFAOYSA-N 1-(4-iodophenyl)piperidin-2-one Chemical compound C1=CC(I)=CC=C1N1C(=O)CCCC1 OYDSTJMVOOOYDW-UHFFFAOYSA-N 0.000 description 1
- QQWORSKLKUMQKP-UHFFFAOYSA-N 1-(4-methoxyphenyl)-7-oxo-6-[3-(2-phenoxyethylamino)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylic acid Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC(=CC=C1)NCCOC1=CC=CC=C1)=O)C(=O)O QQWORSKLKUMQKP-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JMVIVASFFKKFQK-UHFFFAOYSA-N 1-phenylpyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=CC=C1 JMVIVASFFKKFQK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- QDZQGBUZFAVGIW-UHFFFAOYSA-N 1h-pyrazolo[3,4-c]pyridine-3-carboxylic acid Chemical compound N1=CC=C2C(C(=O)O)=NNC2=C1 QDZQGBUZFAVGIW-UHFFFAOYSA-N 0.000 description 1
- CGNAIUUCOVWLLL-UHFFFAOYSA-N 2-(difluoromethoxy)aniline Chemical compound NC1=CC=CC=C1OC(F)F CGNAIUUCOVWLLL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- LNEVUNYUJNORRV-UHFFFAOYSA-N 2-chloro-4-methoxyaniline Chemical compound COC1=CC=C(N)C(Cl)=C1 LNEVUNYUJNORRV-UHFFFAOYSA-N 0.000 description 1
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- YXFAOWYMDGUFIQ-UHFFFAOYSA-N 2-methoxypyridin-3-amine Chemical compound COC1=NC=CC=C1N YXFAOWYMDGUFIQ-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- RSOFZRXRIPVBBM-UHFFFAOYSA-N 3-(difluoromethoxy)aniline Chemical compound NC1=CC=CC(OC(F)F)=C1 RSOFZRXRIPVBBM-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- XQVCBOLNTSUFGD-UHFFFAOYSA-N 3-chloro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1Cl XQVCBOLNTSUFGD-UHFFFAOYSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- LJWAPDSCYTZUJU-UHFFFAOYSA-N 3-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1F LJWAPDSCYTZUJU-UHFFFAOYSA-N 0.000 description 1
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
- MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- YFBMUIMQJYESPZ-UHFFFAOYSA-N 3-phenoxy-1,2-propanediol Natural products C1C(OC(C)=O)CCC2(C)C3=CCC4(C)C(C(C)CCC(CC)C(C)C)CCC4(C)C3CCC21 YFBMUIMQJYESPZ-UHFFFAOYSA-N 0.000 description 1
- FNQIYTUXOKTMDM-UHFFFAOYSA-N 3-phenoxypropane-1,2-diol Chemical compound OCC(O)COC1=CC=CC=C1 FNQIYTUXOKTMDM-UHFFFAOYSA-N 0.000 description 1
- ZFJJCZXQIIVEKF-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide Chemical compound C1NCCC2=C1NN=C2C(=O)N ZFJJCZXQIIVEKF-UHFFFAOYSA-N 0.000 description 1
- CVXBJABYYAWCOT-UHFFFAOYSA-N 4-(4-iodophenyl)morpholin-3-one Chemical compound C1=CC(I)=CC=C1N1C(=O)COCC1 CVXBJABYYAWCOT-UHFFFAOYSA-N 0.000 description 1
- HIDJWBGOQFTDLU-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC(O)=O HIDJWBGOQFTDLU-UHFFFAOYSA-N 0.000 description 1
- MVDCOIIJUOHNKT-UHFFFAOYSA-N 4-[4-[3-ethoxycarbonyl-1-(4-methoxyphenyl)-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridin-6-yl]anilino]-4-oxobutanoic acid Chemical compound C(C)OC(=O)C1=NN(C=2C(N(CCC=21)C1=CC=C(C=C1)NC(CCC(=O)O)=O)=O)C1=CC=C(C=C1)OC MVDCOIIJUOHNKT-UHFFFAOYSA-N 0.000 description 1
- VIBJPUXLAKVICD-UHFFFAOYSA-N 4-bromo-2-chlorophenol Chemical compound OC1=CC=C(Br)C=C1Cl VIBJPUXLAKVICD-UHFFFAOYSA-N 0.000 description 1
- FYAKLZKQJDBBKW-UHFFFAOYSA-N 4-bromo-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1O FYAKLZKQJDBBKW-UHFFFAOYSA-N 0.000 description 1
- RVCJOGNLYVNRDN-UHFFFAOYSA-N 4-bromo-2-methylbenzoic acid Chemical compound CC1=CC(Br)=CC=C1C(O)=O RVCJOGNLYVNRDN-UHFFFAOYSA-N 0.000 description 1
- BGKLFAQCHHCZRZ-UHFFFAOYSA-N 4-iodo-2-methylaniline Chemical compound CC1=CC(I)=CC=C1N BGKLFAQCHHCZRZ-UHFFFAOYSA-N 0.000 description 1
- YBDRFJXGJQULGH-UHFFFAOYSA-N 4-methyl-1h-pyridin-2-one Chemical compound CC1=CC=NC(O)=C1 YBDRFJXGJQULGH-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- ORPHLVJBJOCHBR-UHFFFAOYSA-N 403-19-0 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1F ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 description 1
- XVRIEWDDMODMGA-UHFFFAOYSA-N 5-chloropentan-2-one Chemical compound CC(=O)CCCCl XVRIEWDDMODMGA-UHFFFAOYSA-N 0.000 description 1
- NVRVNSHHLPQGCU-UHFFFAOYSA-N 6-bromohexanoic acid Chemical compound OC(=O)CCCCCBr NVRVNSHHLPQGCU-UHFFFAOYSA-N 0.000 description 1
- UUVDJIWRSIJEBS-UHFFFAOYSA-N 6-methoxypyridin-3-amine Chemical compound COC1=CC=C(N)C=N1 UUVDJIWRSIJEBS-UHFFFAOYSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- JINLNAWIFDXTSI-UHFFFAOYSA-N C(C)(=O)OCCCCN1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(N)=O)=O Chemical compound C(C)(=O)OCCCCN1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(N)=O)=O JINLNAWIFDXTSI-UHFFFAOYSA-N 0.000 description 1
- NONMZDOUXSTOEP-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCN(CC1)C(=O)C1=C(C=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O)C Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C(=O)C1=C(C=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O)C NONMZDOUXSTOEP-UHFFFAOYSA-N 0.000 description 1
- FTYOWDDWQDDYHP-UHFFFAOYSA-N C(C)NC=1C=C(C=CC=1OCCC)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O Chemical compound C(C)NC=1C=C(C=CC=1OCCC)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O FTYOWDDWQDDYHP-UHFFFAOYSA-N 0.000 description 1
- ITLZCLXTGSKZEL-UHFFFAOYSA-N C(N)(=O)C1=NN(C=2C(N(CCC=21)C1=CC=C(OCCCN(C(OC(C)(C)C)=O)C)C=C1)=O)C1=CC=C(C=C1)OC Chemical compound C(N)(=O)C1=NN(C=2C(N(CCC=21)C1=CC=C(OCCCN(C(OC(C)(C)C)=O)C)C=C1)=O)C1=CC=C(C=C1)OC ITLZCLXTGSKZEL-UHFFFAOYSA-N 0.000 description 1
- NVMYTVQJSKRGAE-UHFFFAOYSA-N C(N)(=O)C1=NN(C=2C(N(CCC=21)C=1C=C(C=CC=1)CCN1CCN(CC1)C(=O)OC(C)(C)C)=O)C1=CC=C(C=C1)OC Chemical compound C(N)(=O)C1=NN(C=2C(N(CCC=21)C=1C=C(C=CC=1)CCN1CCN(CC1)C(=O)OC(C)(C)C)=O)C1=CC=C(C=C1)OC NVMYTVQJSKRGAE-UHFFFAOYSA-N 0.000 description 1
- GXMIHVHJTLPVKL-UHFFFAOYSA-N CC(C)C(N(C)C)=O Chemical compound CC(C)C(N(C)C)=O GXMIHVHJTLPVKL-UHFFFAOYSA-N 0.000 description 1
- CDHDVPCLKIEVAK-UHFFFAOYSA-N CC(C1=C(C=C(C=C1)OC)Cl)OC(=O)C2=C3CCNC(=O)C3=NN2 Chemical compound CC(C1=C(C=C(C=C1)OC)Cl)OC(=O)C2=C3CCNC(=O)C3=NN2 CDHDVPCLKIEVAK-UHFFFAOYSA-N 0.000 description 1
- PJLGZYKYJXRPNP-UHFFFAOYSA-N CC(C1=CC(=C(C=C1)OC)F)OC(=O)C2=C3CCNC(=O)C3=NN2 Chemical compound CC(C1=CC(=C(C=C1)OC)F)OC(=O)C2=C3CCNC(=O)C3=NN2 PJLGZYKYJXRPNP-UHFFFAOYSA-N 0.000 description 1
- IUHPZLHUCOTVJJ-UHFFFAOYSA-N CC(C=CN1C)=CC1=O Chemical compound CC(C=CN1C)=CC1=O IUHPZLHUCOTVJJ-UHFFFAOYSA-N 0.000 description 1
- LWOQCYAWZMSQAI-UHFFFAOYSA-N CCC1=C(C=CC(=C1)OC)N2C3=C(CCNC3=O)C(=N2)C(=O)O Chemical compound CCC1=C(C=CC(=C1)OC)N2C3=C(CCNC3=O)C(=N2)C(=O)O LWOQCYAWZMSQAI-UHFFFAOYSA-N 0.000 description 1
- TVHGACRJVAHZLH-UHFFFAOYSA-N CCOC(=O)C(Cl)NNC1=CC=C(OC)C=C1 Chemical compound CCOC(=O)C(Cl)NNC1=CC=C(OC)C=C1 TVHGACRJVAHZLH-UHFFFAOYSA-N 0.000 description 1
- RCUOUMQQVXBRNI-UHFFFAOYSA-N CCOC(c(c(CCN1c(cc2F)ccc2N(CCOC)C(OC(C)(C)C)=O)c2C1=O)n[n]2-c(cc1)ccc1OC)=O Chemical compound CCOC(c(c(CCN1c(cc2F)ccc2N(CCOC)C(OC(C)(C)C)=O)c2C1=O)n[n]2-c(cc1)ccc1OC)=O RCUOUMQQVXBRNI-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N CN(CCC1)C1=O Chemical compound CN(CCC1)C1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- PQVZCPWFOHKCOA-UHFFFAOYSA-N COC1=CC(=C(C=C1)N1N=C(C2=C1C(NCC2)=O)C(=O)OCC)C Chemical compound COC1=CC(=C(C=C1)N1N=C(C2=C1C(NCC2)=O)C(=O)OCC)C PQVZCPWFOHKCOA-UHFFFAOYSA-N 0.000 description 1
- STWNLYPXWRDRRZ-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC(=CC=C1)NCCOC1=CC=CC=C1)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC(=CC=C1)NCCOC1=CC=CC=C1)=O)C(=O)N STWNLYPXWRDRRZ-UHFFFAOYSA-N 0.000 description 1
- JDYLTHHUMFBQGH-UHFFFAOYSA-N COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(C=C(C=C1)C)=O)=O)C(=O)N Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(C=C(C=C1)C)=O)=O)C(=O)N JDYLTHHUMFBQGH-UHFFFAOYSA-N 0.000 description 1
- GLTHXVCOOOWBQN-UHFFFAOYSA-N COc(cc1)ccc1-[n]1nc(C(N)=O)c(CCN2c3cc(CNCCC[n]4cncc4)ccc3)c1C2=O Chemical compound COc(cc1)ccc1-[n]1nc(C(N)=O)c(CCN2c3cc(CNCCC[n]4cncc4)ccc3)c1C2=O GLTHXVCOOOWBQN-UHFFFAOYSA-N 0.000 description 1
- BBEIJEKIRKUTNU-UHFFFAOYSA-N CS(=O)(=O)OCCCCN1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(N)=O)=O Chemical compound CS(=O)(=O)OCCCCN1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(N)=O)=O BBEIJEKIRKUTNU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- NKOUGGSJXHTGAD-UHFFFAOYSA-N ClC=1C=C(C=CC=1OCCCC(C)=O)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O Chemical compound ClC=1C=C(C=CC=1OCCCC(C)=O)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O NKOUGGSJXHTGAD-UHFFFAOYSA-N 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 101710200938 Coagulation factor X inhibitor Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229940123688 Direct Factor Xa inhibitor Drugs 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- RVTSZUXTPNIXMO-UHFFFAOYSA-N O=C1N(C(CC1)=O)C1=CC=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O Chemical compound O=C1N(C(CC1)=O)C1=CC=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)N)=O RVTSZUXTPNIXMO-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
- JHWQMXKQJVAWKI-UHFFFAOYSA-N UNPD187286 Natural products OCC(O)CC1=CC=CC=C1 JHWQMXKQJVAWKI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000007854 aminals Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- YFMGLHFPWAHSKK-UHFFFAOYSA-N ethyl 1-(4-ethoxy-3-fluorophenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound C(C)OC1=C(C=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(CCCC1)=O)=O)C(=O)OCC)F YFMGLHFPWAHSKK-UHFFFAOYSA-N 0.000 description 1
- NOQHFCXLQOLNPT-UHFFFAOYSA-N ethyl 1-(4-methoxyphenyl)-6-[4-(4-methyl-2-oxopyridin-1-yl)phenyl]-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound COC1=CC=C(C=C1)N1N=C(C2=C1C(N(CC2)C1=CC=C(C=C1)N1C(C=C(C=C1)C)=O)=O)C(=O)OCC NOQHFCXLQOLNPT-UHFFFAOYSA-N 0.000 description 1
- DEBPRNDMJGKCBA-UHFFFAOYSA-N ethyl 1h-pyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound N1=CC=C2C(C(=O)OCC)=NNC2=C1 DEBPRNDMJGKCBA-UHFFFAOYSA-N 0.000 description 1
- CAERSDJFKGMKLY-UHFFFAOYSA-N ethyl 2-(3-bromophenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC(Br)=C1 CAERSDJFKGMKLY-UHFFFAOYSA-N 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- FJAKCEHATXBFJT-UHFFFAOYSA-N ethyl 2-oxobutanoate Chemical compound CCOC(=O)C(=O)CC FJAKCEHATXBFJT-UHFFFAOYSA-N 0.000 description 1
- UVAQGQOGOJLALA-UHFFFAOYSA-N ethyl 6-(4-aminophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=NN(C=2C=CC(OC)=CC=2)C(C2=O)=C1CCN2C1=CC=C(N)C=C1 UVAQGQOGOJLALA-UHFFFAOYSA-N 0.000 description 1
- VFTZUMVQPSEGHQ-UHFFFAOYSA-N ethyl 6-[3-methoxy-4-[[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]methyl]phenyl]-1-(4-methoxyphenyl)-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)CC1=C(C=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O)OC VFTZUMVQPSEGHQ-UHFFFAOYSA-N 0.000 description 1
- BPOAYOLPZLCECC-UHFFFAOYSA-N ethyl 6-[4-[3-(dimethylamino)propyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]phenyl]-1-(4-methoxyphenyl)-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound C(C)(C)(C)OC(=O)N(C1=CC=C(C=C1)N1C(C2=C(CC1)C(=NN2C1=CC=C(C=C1)OC)C(=O)OCC)=O)CCCN(C)C BPOAYOLPZLCECC-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- ZRANPIQCGQOGLX-UHFFFAOYSA-N hydrazinyl acetate Chemical compound CC(=O)ONN ZRANPIQCGQOGLX-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- CDGNLUSBENXDGG-UHFFFAOYSA-N meta-Cresidine Chemical compound COC1=CC=C(N)C(C)=C1 CDGNLUSBENXDGG-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical class 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CLSJCGFAWWKELM-UHFFFAOYSA-N tert-butyl n-[2-(4-iodoanilino)-2-oxoethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CC(=O)NC1=CC=C(I)C=C1 CLSJCGFAWWKELM-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011883 total knee arthroplasty Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the invention belongs to the technical field of medicine and relates to a new class of pyrazolo[3,4-c]pyridine derivatives, pharmaceutical compositions containing the same, preparation methods thereof and applications thereof as medicaments.
- Thrombosis is caused by thrombosis and embolism. Under certain pathological conditions, blood components form a blood clot in the blood vessels. The thrombus is detached from the site of formation, and some or all of the veins or blood supply arteries may be blocked during blood flow, causing a series of pathological processes such as blood vessel or systemic ischemia, hypoxia and necrosis. Common thrombosis includes myocardial infarction, cerebral thrombosis, deep vein thrombosis, pulmonary embolism, and peripheral arterial thromboembolism, which seriously endanger people's lives and quality of life. Coronary heart disease is an important class of thrombosis, including myocardial infarction and angina pectoris.
- Thrombosis is caused by activation of both clotting factors and platelets.
- Coagulation factors are a series of protein components involved in blood coagulation. These proteins are activated during vascular bleeding or under pathological conditions and adhere to platelets to form a thrombus.
- endogenous and exogenous coagulation systems in the body.
- the former refers to the activation of blood coagulation factor XII by contact of blood with an abnormal surface.
- the latter activates Factor VII due to tissue damage releasing Factor III. Both can initiate a series of chain reactions and converge at coagulation factor X, which ultimately leads to activation of prothrombin and fibrin formation.
- warfarin inhibits the post-translational modification of coagulation factors VII, IV, X and prothrombin, thereby effectively preventing thrombosis in arteries and veins.
- warfarin has been considerably limited. Patients who use warfarin require monitoring and dose adjustment, and warfarin has a slow onset of action, interacting with other drugs and daily diets, affecting efficacy.
- Heparin is also the main drug in antithrombotic therapy. However, unfractionated heparin is not absorbed orally, and injection is inconvenient. Therefore, more effective oral antithrombotic drugs will have a large market demand in China.
- Factor X is a good target for antithrombotic therapy.
- factor X is upstream of thrombin in the coagulation cascade, and a molecule of factor X is capable of activating hundreds of thrombin molecules. Therefore, in theory, inhibition of factor X is more effective than direct inhibition of thrombin.
- inhibition of factor X does not affect thrombin that has been activated. Reversible factor X inhibitors may also not completely inhibit thrombin generation, while small amounts of thrombin activate platelet support. Hemostasis process. Therefore, inhibition of factor X may have a relatively small bleeding side effect than a direct thrombin inhibitor. This has also been confirmed in animal models.
- the indirect coagulation factor X inhibitor fondaparinux has been clinically successful, demonstrating that inhibition of coagulation factors is indeed an effective means of antithrombotic.
- factor Xa is the most important drug target in the clotting cascade.
- the factor Xa inhibitor binds tightly to the active site of factor Xa, resulting in inactivation of the free and fibrin-binding factor Xa, which acts as an anticoagulant.
- Factor Xa inhibitors significantly reduce the incidence of venous thrombosis compared to low molecular weight heparin without increasing the incidence of bleeding. Compared with warfarin, this kind of medicine not only has the convenience of no need to adjust the dose, no routine monitoring, but also has little interaction with food and medicine, and can be taken at the same time.
- factor Xa inhibitors Although the bleeding tendency of factor Xa inhibitors is lower than that of traditional anticoagulants, the main clinical adverse reactions are still bleeding, so reducing the risk of bleeding and improving the therapeutic window are the research hotspots in this field.
- the present invention provides a novel compound with a good antithrombotic effect and a lower risk of bleeding.
- such a compound is a compound of the following technical schemes 1-13.
- X is selected from CH and N;
- R Na and R Nb are each independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy-C 0-6 alkyl, (C 0-6 alkyl)(C 0-6 alkyl)NC 1-6 alkyl, (C 2-6 alkylene)NC 1-6 alkyl or carbamoyl-C 1-6 alkyl;
- R Na and R Nb together with their respective attached atoms form a 5, 6 or 7 membered ring
- the 5, 6 or 7 membered ring is substituted by 1 R Ng , wherein the R Ng is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxy, C 1-4 alkoxy, halogen, oxo and amino.
- the 5, 6 or 7 membered ring in addition to the N atom to which R Nb is attached, further comprises 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, N and S,
- the 5, 6 or 7 membered ring includes 0, 1, 2 or 3 double bonds
- R Nc is selected from the group consisting of hydrogen, C 1-6 alkyl and C 1-6 alkoxy;
- R Nd is selected from the group consisting of hydrogen, C 1-6 alkoxy, halogen substituted C 1-6 alkoxy, carbamoyl-C 1-6 alkyl and C 1-6 alkoxy-C 1-6 alkyl ;
- R Ne is selected from the group consisting of hydrogen, halogen, C 1-6 alkoxy, halogen substituted C 1-6 alkoxy, carbamoyl-C 1-6 alkyl and C 1-6 alkoxy-C 1-6 alkyl;
- R Nf is selected from the group consisting of hydrogen, halogen, C 1-6 alkoxy, halogen substituted C 1-6 alkoxy, carbamoyl-C 1-6 alkyl and C 1-6 alkoxy-C 1-6 alkyl;
- X is CH.
- R Na and R Nb together with their respective attached atoms form a 5, 6 or 7 membered ring
- the 5, 6 or 7 membered ring is substituted by 1 R Ng , wherein the R Ng is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxy, C 1-4 alkoxy, halogen, oxo and amino.
- the 5, 6 or 7 membered ring in addition to the N atom to which R Nb is attached, further comprises 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, N and S,
- the 5, 6 or 7 membered ring includes 0, 1, 2 or 3 double bonds.
- Z is selected from:
- R Nc is selected from the group consisting of hydrogen and methyl.
- R Nd is selected from C 1-3 alkoxy groups.
- R Ne is selected from the group consisting of hydrogen, chlorine and fluorine.
- R Nf is selected from the group consisting of hydrogen, chlorine and fluorine.
- R Na and R Nb together with their respective attached atoms form a 5, 6 or 7 membered ring
- the 5, 6 or 7 membered ring is substituted by 1 R Ng , wherein the R Ng is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxy, C 1-4 alkoxy, halogen, oxo and amino.
- the 5, 6 or 7 membered ring in addition to the N atom to which R Nb is attached, further comprises 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, N and S,
- the 5, 6 or 7 membered ring includes 0, 1, 2 or 3 double bonds
- R Nd is selected from C 1-6 alkoxy
- At least one of R Nc , R Ng , R Ne and R Nf is not hydrogen.
- X is CH
- R Na and R Nb together with their respective attached atoms form a 5, 6 or 7 membered ring
- the 5, 6 or 7 membered ring is substituted by 1 R Ng , wherein the R Ng is selected from the group consisting of hydrogen and methyl.
- the 5, 6 or 7 membered ring in addition to the N atom to which R Nb is attached, further comprises 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, N and S,
- the 5, 6 or 7 membered ring includes 0, 1, 2 or 3 double bonds
- R Nd is selected from the group consisting of ethoxy
- At least one of R Nc , R Ng , R Ne and R Nf is not hydrogen.
- X is CH
- R Na and R Nb together with their respective attached atoms form a 5, 6 or 7 membered ring
- the 5, 6 or 7 membered ring is substituted by 1 R Ng , wherein the R Ng is selected from the group consisting of hydrogen and methyl.
- the 5, 6 or 7 membered ring in addition to the N atom to which R Nb is attached, further comprises 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, N and S,
- the 5, 6 or 7 membered ring includes 0, 1, 2 or 3 double bonds
- R Nd is selected from the group consisting of ethoxy
- R Nc is a methyl group.
- Z is selected from:
- the present invention also provides a novel pharmaceutical composition having a good antithrombotic effect and a lower risk of bleeding, which comprises the compound of the formula (I) according to any one of the above aspects 1-13, which is mutually transformed.
- the present invention also provides the compound of the formula (I) according to any one of the above aspects 1-13, the tautomer thereof, the optical isomer thereof, or a pharmaceutically acceptable salt thereof, or the above-mentioned technique
- the disease is selected from the group consisting of myocardial infarction, angina pectoris, angioplasty or aortic coronary artery shunt re-obstruction and restenosis, stroke, transient local exacerbation, peripheral arterial occlusive disease, pulmonary embolism or deep vein thrombosis.
- the present invention also provides a method for producing a compound according to the above aspect 1 or a tautomer thereof, an optical isomer thereof, and a pharmaceutically acceptable salt thereof, which comprises subjecting a compound of the formula (II) to amination.
- a method for producing a compound according to the above aspect 1 or a tautomer thereof, an optical isomer thereof, and a pharmaceutically acceptable salt thereof which comprises subjecting a compound of the formula (II) to amination.
- the present invention also provides the compound of the formula (I) according to any one of the above aspects 1-13, the tautomer thereof, the optical isomer thereof, or a pharmaceutically acceptable salt thereof, or the above-mentioned technique
- the pharmaceutical composition of the regimen is prepared for the prevention and/or treatment of a factor Xa positive affecting disease in the case of a low risk of bleeding (for example, in the case of a lower risk of bleeding with apixaban)
- the disease is, for example, selected from thromboembolism, and disseminated intravascular coagulation; for example, the disease is selected from the group consisting of myocardial infarction, angina pectoris, angioplasty, or aortic coronary artery shunt Obstruction and restenosis, stroke, transient localized episodes, peripheral arterial occlusive disease, pulmonary embolism, or deep vein thrombosis.
- Geometric isomers may be present in the present compounds.
- the compounds of the invention may contain a carbon-carbon double bond or a carbon-nitrogen double bond in the E or Z configuration, wherein the term “E” represents a higher order substituent on the opposite side of the carbon-carbon or carbon-nitrogen double bond, the term “Z” represents a higher order substituent on the same side of the carbon-carbon or carbon-nitrogen double bond (determined using the Cahn-Ingold Prelog precedence rule).
- the compounds of the invention may also exist in the form of a mixture of "E” and "Z” isomers. Substituents around a cycloalkyl or heterocycloalkyl group are referred to as cis or trans configurations.
- the compounds of the invention may contain asymmetrically substituted carbon atoms in the R or S configuration, wherein the terms "R” and "S” are as defined by IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13. -10 is defined.
- Compounds with asymmetrically substituted carbon atoms (having equal numbers of R and S configurations) are racemic at those carbon atoms.
- An atom having an excess of one configuration (relative to the other) provides a higher number of such configurations, preferably an excess of about 85% to 90%, more preferably an excess of about 95% to 99%, and even more preferably an excess of greater than about 99%.
- the invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers.
- the compound of the present invention containing a NH, C(O)NH 2 , OH or SH moiety may have a prodrug-forming moiety attached thereto.
- the moiety forming the prodrug is removed by metabolic processes and the compound having a free hydroxyl group, amino group or carboxylic acid is released in vivo.
- Prodrugs are useful for modulating the pharmacokinetic properties of a compound, for example, solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue permeability, and clearance.
- Prodrugs are derivatives of designed active drugs that can improve certain defined, undesirable physical or biological properties. Physical properties are usually related to solubility (too high or insufficient lipid or water solubility) or stability, while problematic biological properties include too fast metabolism or poor bioavailability, which may itself be related to physicochemical properties.
- Prodrugs are generally prepared as follows: a) forming esters, half esters, carbonates, nitrates, amides, hydroxamic acids, carbamates, imines, Mannich bases, phosphates, phosphates and Enamine, b) functionalize the drug with azo, glycoside, peptide and ether functional groups, c) use of the drug's aminal, hemiacetal, polymer, salt, complex, phosphoramide, acetal, half Acetal and ketal forms. See, for example, Andrejus Korolkovas's, "Essentials of Medicinal Chemistry", John Wiley-Interscience Publications, John Wiley and Sons, New York (1988), pp.
- Esters can be prepared from substrates containing hydroxyl or carboxyl groups using conventional methods known to those skilled in the art. A typical reaction for these compounds is to replace one hetero atom with another.
- the amide can be prepared in a similar manner from a substrate containing an amino group or a carboxyl group. The ester can also react with an amine or ammonia to form an amide. Another way to prepare the amide is to heat the carboxylic acid together with the amine.
- the compounds of the present invention may exist in isotopically traced or enriched form, containing one or more atoms having atomic or mass numbers different from the atomic mass or mass of the largest amount of atoms found in nature.
- An isotope can be a radioactive or non-radioactive isotope.
- Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine and iodine include, but are not limited to: 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 32 P, 35 S, 18 F, 36 Cl and 125 I.
- Compounds containing other isotopes of these and/or other atoms are within the scope of the invention.
- tautomer refers to a functional group isomer that is produced by the rapid movement of an atom in two positions in a molecule, which can be converted to each other, usually reaching a state in a certain state.
- optical isomer refers to a substance having the same molecular structure, similar physicochemical properties, but different optical rotation.
- salt as used herein is selected from the group consisting of: hydrochloride, hydrobromide, sulfate, sulfite, phosphate, methanesulfonate, p-toluenesulfonate, maleate, tartrate, malic acid. Salt, fumarate, citrate, etc.
- C 1-6 alkyl refers to a straight or branched chain saturated hydrocarbon group containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl. , isobutyl, sec-butyl, tert-butyl, and the like.
- C 2-6 alkenyl refers to a straight or branched chain unsaturated hydrocarbon group containing from 2 to 6 carbon atoms and containing at least one double bond, including but not limited to vinyl, 1- Propylene, 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like.
- C 2-6 alkynyl refers to a straight or branched chain unsaturated hydrocarbon group containing from 2 to 6 carbon atoms and containing at least one triple bond, including but not limited to ethynyl, propynyl. , butynyl and the like.
- halogen means fluoro, chloro, bromo or iodo.
- C1-6 alkoxy refers to " C1-6 alkyl-O-" wherein C1-6 alkyl is as defined above.
- carbamoyl refers to the "NH 2 -CO-”.
- C 2-6 alkylene refers to a divalent group formed by the loss of two hydrogen atoms from a C 2-6 alkane, including but not limited to 1,2-ethylene, 1,3 - propylene, 1,4-butylene, and the like.
- C 0-6 alkyl is a collective term for a bond and "C 1-6 alkyl”.
- C 1-6 alkoxy-C 0-6 alkyl refers to a C 0-6 alkyl group substituted by a C 1-6 alkoxy group
- C 1-6 alkoxy-C 0 Alkyl means "C 1-6 alkoxy”.
- (C 0-6 alkyl)(C 0-6 alkyl)NC 1-6 alkyl refers to a C 1-6 alkyl group substituted with an amino group, wherein the amino group is further A C 0-6 alkyl group which is independent of each other, and a C 0 alkyl group means that it is not substituted.
- (C 2-6 alkylene)NC 1-6 alkyl is a C 1-6 alkyl group substituted by an amino group, wherein the N atom in the amino group is the same as the C 2 - The 6 alkylene group forms a saturated ring.
- carbamoyl- C1-6 alkyl refers to a C1-6 alkyl group substituted with a carbamoyl group.
- the term "5, 6 or 7 membered ring” refers to a ring containing 5, 6 or 7 ring atoms, said ring comprising at least one nitrogen atom as a ring atom, and in addition to the nitrogen atom, said The 5, 6 or 7 membered ring may further comprise 0, 1, 2, 3 or 4 heteroatoms selected from O, N and S; said 5, 6 or 7 membered ring comprising 0, 1, 2 or 3 Double bond; the 5, 6 or 7 membered ring may be substituted by an oxo group; the 5, 6 or 7 membered ring may be in the form of a monocyclic or bridged ring.
- the 5, 6 or 7 membered ring includes, but is not limited to, pyrrole, dihydropyrrole, pyrrolidine, pyridine, dihydropyridine, tetrahydropyridine, piperidine, morpholine, piperazine, azepane, 2- Azabicyclo[2.2.1]heptane and the like.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention, or a tautomer thereof, an optical isomer thereof, and a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition of the present invention may be suitably used in an orally administered form such as granules, tablets or capsules, and parenteral injections include intravenous, subcutaneous, intramuscular, intrathecal, or infusion forms such as sterile solutions, suspensions. Or an emulsion, a topical application form such as an ointment or cream, or a rectal administration form such as a suppository.
- parenteral injections include intravenous, subcutaneous, intramuscular, intrathecal, or infusion forms such as sterile solutions, suspensions.
- an emulsion, a topical application form such as an ointment or cream
- a rectal administration form such as a suppository.
- the above composition can be prepared by a conventional method using a conventional excipient.
- the present invention provides a compound of the present invention, or a tautomer thereof, an optical isomer thereof, and a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for preparation For treatment Use in the prevention and/or treatment of a medicament for inhibiting the positive effects of factor Xa on a disease.
- the disease is, for example, selected from thromboembolism and disseminated intravascular coagulation.
- the disease is selected from the group consisting of myocardial infarction, angina pectoris, angioplasty or aortic coronary artery shunt re-obstruction and restenosis, stroke, transient local exacerbation, peripheral arterial occlusive disease, pulmonary embolism or deep vein thrombosis form.
- the present invention provides a method for producing a compound of the present invention or a tautomer thereof, an optical isomer thereof, and a pharmaceutically acceptable salt thereof, comprising the formula (II)
- the compound is subjected to amination to give a compound of formula (I):
- the compounds of the invention have a good antithrombotic effect and a lower risk of bleeding. These effects can be confirmed by the following biological activity studies.
- Buffer 50 mM TrisHCl, 150 mM NaCl, pH 8.3
- Example section Example number The ratio of the IC50 value of the compound of the invention to the IC50 value of apixaban B twenty one less than 1 B 26 less than 1 B 29 less than 1 B 32 less than 1
- Arteriovenous bypass tube homemade. It includes the following parts: the middle thick tube is a human infusion tube, the length is 8cm, and the two sides of the thin tube are disposable venous blood collection needles, each 10cm long.
- the middle thick tube was fixed with a 6 cm long surgical line in the direction of the common carotid artery and weighed in advance.
- the arteriovenous bypass tube was filled with 3.125 U/ml heparin physiological saline solution.
- thrombus inhibition rate was calculated by comparison with the thrombus weight of the solvent control group.
- test compound inhibited the venous bypass thrombosis in rats by more than 60% (preferably more than 70%), and both had strong inhibitory activity.
- the starting compounds are synthesized by the methods described herein or are commercially available and are purchased from the following manufacturers: BEHRINGER, Beijing Yinuokai Technology Co., Ltd., Aladdin Reagent, Alfa Aisha, Suiyuan Chemical Technology ( Shanghai Co., Ltd.
- Compound A is a raw material which is commercially available.
- Compound C1 and Compound C2 are commercially available.
- Step 1 Preparation of compound F-b, same as method 1.
- Step 2 Preparation of compound F-c, same as method 1.
- reaction flask In 50 ml reaction flask was charged compound Fa (e.g. 20.0 mmol) alkylamine (e.g. methylamine or isopropylamine) aqueous solution (e.g., 60.0 mmol) and K 2 CO 3 (e.g., 5.5 g, 39.8 mmol Molar), then add DMF (eg 30 ml). The resulting mixture was heated to 50 ° C and reacted for 4 hours. After the reaction was completed, the resulting mixture was cooled to room temperature, and purified water was added thereto. The resulting mixture was filtered to give the product in a yield of about 80%.
- Fa e.g. 20.0 mmol
- alkylamine e.g. methylamine or isopropylamine
- K 2 CO 3 e.g., 5.5 g, 39.8 mmol Molar
- Compound II (e.g., 0.45 mmol) is added to a sealed tube and then ethylene glycol (e.g., 10 mL) is added. The resulting mixture was stirred. The ammonia gas was then introduced into the sealed tube for 0.5 hours. The sealed tube was sealed and heated to 120 ° C for 3 hours. The resulting mixture was cooled to room temperature and poured into cold water, a solid precipitated, filtered, and dried to give the title compound.
- ethylene glycol e.g. 10 mL
- the present invention also provides the following compounds 1-35 which correspond to the compounds of Examples 1-35, respectively.
- Step 2 Preparation of tert-butyl 2-(4-iodophenylamino)-2-oxoethyl (methyl)carbamate
- Step 3 Preparation of tert-butyl 2-(4-iodophenylamino)ethyl (methyl)carbamate
- tert-Butyl 2-(4-iodophenylamino)-2-oxoethyl(methyl)carbamate (2.0 g, 5.12 mmol) was dissolved in THF (20 mL). The resulting mixture was cooled to 0 ° C, and a borane tetrahydrofuran solution (16 ml) was added dropwise. After the completion of the dropwise addition, the resulting mixture was heated to 50 ° C, and the reaction was stirred for 14 hours. The resulting mixture was then cooled to about 0 ° C, and methanol (0.82 g, 25.6 mmol) was added. The resulting mixture was heated to 80 ° C and stirred for 2 hours.
- the obtained mixture was concentrated, and n-butanol (10 ml) and toluene (40 ml) were added to the obtained concentrate.
- the resulting mixture was stirred at 80 ° C for 14 hours. Will get The resulting mixture was concentrated to give a crude material.
- the obtained crude product was purified by silica gel column chromatography (dichloromethane:methanol: 50:1) to yield 3.9 g of the desired compound as a desired compound (yield: 57.7%).
- Step 1 Preparation of (4-bromo-2-hydroxyphenyl)(4-tert-butoxycarbonylpiperazin-1-yl)methanone
- N-(1-Methyl-1H-pyrazol-5-yl)formyl-3-bromoaniline (1.0 g, 3.6 mmol) was dissolved in THF (20 mL).
- LiAlH 4 (0.35 g, 9 mmol) was added portionwise under ice bath. The resulting mixture was stirred at 40 ° C for 14 hours after the addition was completed. After the reaction was completed, water was added to the obtained mixture to quench the reaction. The resulting mixture was then extracted with ethyl acetate. The obtained organic phase was concentrated under reduced pressure to give a white solid (yel.
- N-Phenyl-2-pyrrolidone (5.0 g, 31 mmol), NIS (10.4 g, 46 mmol), cesium carbonate (340 mg), and acetic acid (100 mL) were sequentially added to the reaction flask at room temperature. The resulting mixture was warmed to 100 ° C and reacted for 4 hours. Then, the resulting mixture was poured into water (650 ml). The resulting mixture was extracted with ethyl acetate. The obtained organic phase was washed with a saturated aqueous The obtained filtrate was concentrated to give 6.15 g of a brown solid (yield: 69.1%).
- m-Nitrobenzyl alcohol (3.3 g, 21.5 mmol), ethyl bromide (3.5 g, 32.3 mmol) and potassium hydroxide (2.4 g, 43.0 mmol) were added to DMSO (20 mL) at room temperature. . After the addition was completed, the resulting mixture was stirred and reacted at room temperature for 6 hours. After completion of the reaction, ethyl acetate and water were added thereto, and the mixture was stirred and allowed to stand for liquid separation. The aqueous phase was extracted with EtOAc.
- Preparation 22 Preparation of 1-(4-methoxyphenyl)-6-(4-iodophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazole[3 , 4-c]pyridine-3-carboxylic acid ethyl ester
- Step 1 Preparation of ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazinyl)acetate
- Step 2 Preparation of 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ester
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(4-(N-tert-butoxycarbonyl-3-dimethylaminopropylamino)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- N-(3-Dimethylaminopropyl)-N-tert-butoxycarbonyl-4-iodoaniline (930 mg, 2.30 mmol), 1-(4-methoxyphenyl)- Ethyl 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate (604 mg, 1.92 mmol), potassium carbonate (530 mg, 3.83 mmol), 1,10-phenanthroline (138 mg, 0.77 mmol) and Cuprous iodide (73 mg, 0.38 mmol) was dispersed in dimethyl sulfoxide (10 mL).
- the resulting mixture was warmed to 120 ° C under a nitrogen atmosphere, and the reaction was stirred for 14 hours. After the reaction was completed, the obtained mixture was cooled and poured into ice water (50 ml). The resulting mixture was extracted with dichloromethane. The obtained organic phase was concentrated under reduced pressure to give a crude material.
- Step 4 Preparation of 1-(4-methoxyphenyl)-6-(4-(N-tert-butoxycarbonyl-3-dimethylaminopropylamino)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 5 Preparation of 1-(4-methoxyphenyl)-6-(4-(3-(N,N-dimethylamino)propylamino)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(3-(N-tert-butoxycarbonyl-N-methylamino)propoxy)phenyl)-7-oxo Generation of 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(3-(N-tert-butoxycarbonyl-N-methylamino)propoxy)phenyl)-7-oxo Generation-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(4-(3-(N-methylamino)propoxy)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-fluoro-4-((N-tert-butoxycarbonyl-N-methoxyethyl)amino)phenyl)-7- Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- N-tert-Butoxycarbonyl-N-methoxyethyl-4-bromo-2-fluoroaniline (862 mg, 2.48 mmol), 1-(4-methoxyphenyl)-7, at room temperature -oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester (600 mg, 1.91 mmol), potassium carbonate (1050 mg, 7.62 Millimol), potassium iodide (700 mg, 4.22 mmol), cuprous iodide (145 mg, 0.76 mmol) and N,N'-dimethylethylenediamine (84 mg, 0.95 mmol) in dimethyl In the sulfoxide (10 ml).
- the resulting mixture was warmed to 120 ° C under a nitrogen atmosphere and stirred overnight. After dropping to room temperature, the resulting mixture was poured into ice water (50 ml). The resulting mixture was extracted with dichloromethane. The obtained organic phase was concentrated under reduced pressure to give a crude material. The obtained crude product was purified to silica gel column chromatography (Dm.
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-fluoro-4-((N-tert-butoxycarbonyl-N-methoxyethyl)amino)phenyl)-7- Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(3-fluoro-4-((2-methoxy)ethylamino)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-methyl-4-(4-(N-tert-butoxycarbonylamino)butyryl)phenyl)-7-oxo Generation of 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- the resulting mixture was heated to 120 ° C under a nitrogen atmosphere, and the reaction was stirred for 14 hours. After dropping to room temperature, the resulting mixture was poured into ice water (40 ml). The resulting mixture was extracted with ethyl acetate. The resulting organic phase was concentrated under reduced pressure to give a crude material. The obtained crude product was purified to silica gel column chromatography (dichloromethanol:methanol: 50:1).
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-methyl-4-(4-(N-tert-butoxycarbonylamino)butyryl)phenyl)-7-oxo Generation-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(3-methyl-4-(4-aminobutyryl)phenyl)-7-oxo-4,5,6,7 -tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-ethylamino-4-propoxyphenyl)-7-oxo-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-ethylamino-4-propoxyphenyl)-7-oxo-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(2-(N-methyl-N-tert-butoxycarbonylamino)ethylamino)phenyl)-7-oxo Generation of 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(2-(N-methyl-N-tert-butoxycarbonylamino)ethylamino)phenyl)-7-oxo Generation-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(4-(2-(N-methylamino)ethylamino)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Example 7 1-(4-Methoxyphenyl)-6-(3-chloro-4-((4-oxo)pentyloxy)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-chloro-4-((4-oxo)pentyloxy)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-chloro-4-((4-oxo)pentyloxy)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(4-methylpiperazin-1-yl)phenyl)-7-oxo-4,5,6,7- Ethyl tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(4-methylpiperazin-1-yl)phenyl)-7-oxo-4,5,6,7- Tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-(2-(4-tert-butoxycarbonylpiperazin-1-yl)ethyl)phenyl)-7-oxo- Ethyl 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-(2-(4-tert-butoxycarbonylpiperazin-1-yl)ethyl)phenyl)-7-oxo- 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(3-(2-piperazin-1-ylethyl)phenyl)-7-oxo-4,5,6,7- Tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-methoxy-4-(4-tert-butoxycarbonylpiperazin-1-yl)methylphenyl)-7-oxo Generation of 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-methoxy-4-(4-tert-butoxycarbonylpiperazin-1-yl)methylphenyl)-7-oxo Generation-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(3-methoxy-4-(piperazin-1-yl)methylphenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-methyl-4-((4-tert-butoxycarbonylpiperazin-1-yl)formyl)phenyl)-7- Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-methyl-4-((4-tert-butoxycarbonylpiperazin-1-yl)formyl)phenyl)-7- Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(3-methyl-4-(piperazin-1-ylformyl)benzene -7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-(phenoxyethylamino)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H- Pyrazolo[3,4-c]pyridine-3-carboxylic acid
- N-(3-bromophenyl)-2-phenoxyethylamine (2.0 g, 6.8 mmol), 1-(4-methoxyphenyl)-7-oxo-4, at room temperature 5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester (2.1 g, 6.8 mmol), K 3 PO 4 (5.0 g, 23.5 mmol), CuI (260 mg, 1.36 mmol) and dimethylethylenediamine (250 mg, 2.8 mmol) were dissolved in DMSO (30 mL). After the nitrogen exchange, the resulting mixture was warmed to 120 ° C, and the reaction was stirred for 14 hours.
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-(phenoxyethylamino)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H- Ethyl pyrazolo[3,4-c]pyridine-3-carboxylate
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(3-(phenoxyethylamino)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H- Pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-(((1-methyl-1H-pyrazol-5-yl)methyl))amino)phenyl)-7- Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-(((1-methyl-1H-pyrazol-5-yl)methyl))amino)phenyl)-7- Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(3-(((1-methyl-1H-pyrazol-5-yl)methyl))amino)phenyl)-7- Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(3-(N-(3-(1H-imidazol-1-yl)propyl)aminemethyl)phenyl)-7-oxo Generation of 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(3-(N-(3-(1H-imidazol-1-yl)propyl)aminemethyl)phenyl)-7-oxo Generation-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(acetoxy)-n-butyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyridyl Ethylzolo[3,4-c]pyridine-3-carboxylate
- the resulting organic phase was concentrated under reduced pressure to give a crude material.
- the obtained crude product was purified by silica gel column chromatography (dichlorodiethyldiethyldiethyldiethyldiethyldiethyldiethyldiethyldiethyldiethyldiaminediethyldiethyldiethyldiethyldiaminediaminediethyldiethyldiaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediaminediamine
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(acetoxy)-n-butyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyridyl Zoxa[3,4-c]pyridine-3-carboxamide
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(4-(methylsulfonyloxy) n-butyl)-7-oxo-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 4 Preparation of 1-(4-methoxyphenyl)-6-(4-(piperidin-1-yl)butyl)-7-oxo-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(isobutyryl)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyridyl Ethylzolo[3,4-c]pyridine-3-carboxylate
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(isobutyryl)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyridyl Zoxa[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(2-oxopyrrolidin-1-yl)phenyl)-7-oxo-4,5,6,7- Ethyl tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(2-oxopyrrolidin-1-yl)phenyl)-7-oxo-4,5,6,7- Tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Example 18 1-(3-Chloro-4-methoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(3-chloro-4-methoxyphenyl)hydrazinyl)acetate
- Step 2 Preparation of 1-(3-chloro-4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine- Ethyl 3-carboxylate
- Step 3 Preparation of 1-(3-chloro-4-methoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(3-chloro-4-methoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(2-methoxypyridin-5-yl)hydrazinyl) ethyl acetate
- Step 2 Preparation of 1-(2-methoxypyridin-5-yl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3 -ethyl formate
- Step 3 Preparation of 1-(2-methoxypyridin-5-yl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(2-methoxypyridin-5-yl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(3-difluoromethoxyphenyl)hydrazinyl) ethyl acetate
- Step 3 Preparation of 1-(3-difluoromethoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(3-difluoromethoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(2-chloro-4-methoxyphenyl)hydrazinyl)acetate
- Step 3 Preparation of 1-(2-chloro-4-methoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(2-chloro-4-methoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(2-methyl-4-methoxyphenyl)hydrazinyl) ethyl acetate
- Step 3 Preparation of 1-(2-methyl-4-methoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4, Ethyl 5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
- Step 4 Preparation of 1-(2-methyl-4-methoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4, 5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(2-methoxypyridin-3-yl)hydrazinyl) ethyl acetate
- Step 2 Preparation of 1-(2-methoxypyridin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3 -ethyl formate
- Step 3 Preparation of 1-(2-methoxypyridin-3-yl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(2-methoxypyridin-3-yl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(2-difluoromethoxyphenyl)hydrazinyl)acetate
- 2-Difluoromethoxyaniline (24.0 g, 0.15 mol) was added to water (120 mL) at room temperature. The resulting mixture was stirred and cooled to -5 to 0 °C. Concentrated hydrochloric acid (40 ml), sodium nitrite solution (66 ml), ethyl 2-chloro-3-oxobutanoate (25.2 g, 0.15 mol) in ethanol (120 ml) was added to the mixture. And an aqueous solution of sodium acetate (36.9 g, 0.45 mol) (360 ml). After the completion of the dropwise addition, the resulting mixture was stirred at low temperature for 0.5 hour.
- Step 3 Preparation of 1-(2-difluoromethoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(2-difluoromethoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(4-(2-ethoxy-2-oxo)ethoxyphenyl)hydrazinyl) ethyl acetate
- Step 2 Preparation of 1-(4-(2-ethoxy-2-oxoethoxy)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazole [ Ethyl 3,4-c]pyridine-3-carboxylate
- Step 3 Preparation of 1-(4-(2-ethoxy-2-oxoethoxy)phenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)- Ethyl 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
- Step 4 Preparation of 1-(4-(2-oxo-2-aminoethoxy)phenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7 -oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(3-fluoro-4-methoxyphenyl)hydrazinyl)acetate
- Step 2 Preparation of 1-(3-fluoro-4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine- Ethyl 3-carboxylate
- Step 3 Preparation of 1-(3-fluoro-4-methoxyphenyl)-6-(4-(3-oxomorpholin-4-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(3-fluoro-4-methoxyphenyl)-6-(4-(3-oxomorpholin-4-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(3-fluoro-4-methoxyphenyl)-6-(4-(2-oxo-1H-pyrrolidin-1-yl)phenyl)-7-oxo-4 ,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(3-fluoro-4-methoxyphenyl)-6-(4-(2-oxo-1H-pyrrolidin-1-yl)phenyl)-7-oxo-4 ,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Example 28 Preparation of 1-(4-methoxyphenyl)-6-(4-(N-methyl-N-isobutyrylamino)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(N-methyl-N-isobutyrylamino)phenyl)-7-oxo-4,5,6, Ethyl 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
- N-methyl-N-isobutyryl-4-iodoaniline (1.00 g, 3.3 mmol), 1-(4-methoxyphenyl)-7-oxo-4,5, at room temperature ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester (0.95 g, 3.0 mmol), 1,10-phenanthroline (0.25 g, 1.41) Millimol), potassium carbonate (0.87 g, 6.3 mmol) was added to DMSO (5 mL). The resulting mixture was stirred for 12 hours under a nitrogen atmosphere at 120 °C. The resulting mixture was poured into ice water (50 ml). The resulting mixture was extracted with ethyl acetate. The obtained organic phase was concentrated under reduced pressure to give a crude material. The obtained crude product was purified by prep-HPLC to yield 0.15 g (yield: 10.2%).
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(N-methyl-N-isobutyrylamino)phenyl)-7-oxo-4,5,6, 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(3-fluoro-4-ethoxyphenyl)hydrazinyl)acetate
- Step 3 Preparation of 1-(3-fluoro-4-ethoxyphenyl)-6-(4-(piperidin-2-one-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 4 Preparation of 1-(3-fluoro-4-ethoxyphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(6-bromohexanoyl)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- 6-Bromohexanoic acid (2.02 g, 10.4 mmol), 4-dimethylaminopyridine (DMAP) (0.20 g, 1.64 mmol), 1-(4-methoxyphenyl)- 6-(4- Aminophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester (4.00 g, 9.8 mmol) was added to In methyl chloride (40 ml). The resulting mixture was stirred and reacted at room temperature for 4 hours. After the reaction was completed, the obtained mixture was evaporated. (Yield 47.2%).
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(2-oxoazepane-1-yl)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(4-(2-oxoazepan-1-yl)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of ethyl 2-chloro-2-(2-(3-ethoxymethylphenyl) fluorenyl) ethyl acetate
- Step 3 Preparation of 1-(3-ethoxymethylphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5,6, Ethyl 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
- Step 4 Preparation of 1-(3-ethoxymethylphenyl)-6-(4-(piperidin-2-oxo-1-yl)phenyl)-7-oxo-4,5,6, 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(3-methyl-2-oxopyridin-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(3-methyl-2-oxopyridin-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(4-methyl-2-oxopyridin-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(4-methyl-2-oxopyridin-1-yl)phenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- Step 1 Preparation of 1-(4-methoxyphenyl)-6-(4-(carboxyethylcarbonylamino)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- 1,4-Succinic acid (2.4 g, 20 mmol), EDCI (11.4 g, 60 mmol), 4-dimethylaminopyridine (DMAP) (0.4 g, 3.3 mmol), 1-(4-Methoxyphenyl)-6-(4-aminophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]
- Ethyl pyridine-3-carboxylate (8.2 g, 20 mmol) was added to dichloromethane (60 mL). The resulting mixture was stirred and reacted for 3 hours at room temperature.
- Step 2 Preparation of 1-(4-methoxyphenyl)-6-(4-(2,5-dioxopyrrolidin-1-yl)phenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
- Step 3 Preparation of 1-(4-methoxyphenyl)-6-(4-(4-amino-4-carbonylbutyryl)phenyl)-7-oxo-4,5,6,7- Tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
实施例部分 | 实施例编号 | 本发明化合物的IC50值/阿哌沙班的IC50值的比值 |
B | 21 | 小于1 |
B | 26 | 小于1 |
B | 29 | 小于1 |
B | 32 | 小于1 |
B | 33 | 小于1 |
A | 3 | 小于1 |
A | 16 | 小于1 |
A | 17 | 小于1 |
A | 19 | 小于1 |
A | 27 | 小于2 |
A | 28 | 小于1 |
A | 29 | 小于2 |
A | 30 | 小于2 |
A | 31 | 小于1 |
A | 32 | 小于1 |
A | 33 | 小于1 |
A | 34 | 小于1 |
A | 35 | 小于2 |
A | 36 | 小于1 |
A | 37 | 小于1 |
A | 38 | 小于1 |
A | 39 | 小于1 |
A | 40 | 小于1 |
A | 47 | 小于1 |
A | 48 | 小于1 |
A | 50 | 小于1 |
A | 51 | 小于1 |
化合物 | X | R3 |
C1 | H | CH3 |
C2 | H | Et |
C3 | F | CH3 |
C4 | F | Et |
C5 | F | i-Pr |
C6 | Cl | Et |
Claims (21)
- 式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐:其中X选自CH和N;RNa和RNb各自独立地选自氢、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基-C0-6烷基、(C0-6烷基)(C0-6烷基)N-C1-6烷基、(C2-6亚烷基)N-C1-6烷基或氨基甲酰基-C1-6烷基;或者RNa和RNb与其各自相连的原子一起形成5、6或7元环,其中所述5、6或7元环被1个RNg取代,其中所述RNg选自氢、C1-4烷基、羟基、C1-4烷氧基、卤素、氧代和氨基,所述5、6或7元环,除与RNb连接的N原子以外,还包括0、1、2、3或4个杂原子,所述杂原子选自O、N和S,所述5、6或7元环包括0、1、2或3个双键;RNc选自氢、C1-6烷基和C1-6烷氧基;RNd选自氢、C1-6烷氧基、卤素取代的C1-6烷氧基、氨基甲酰基-C1-6烷基和C1-6烷氧基-C1-6烷基;RNe选自氢、卤素、C1-6烷氧基、卤素取代的C1-6烷氧基、氨基甲酰基-C1-6烷基和C1-6烷氧基-C1-6烷基;RNf选自氢、卤素、C1-6烷氧基、卤素取代的C1-6烷氧基、氨基甲酰基-C1-6烷基和C1-6烷氧基-C1-6烷基;前提是所述式(I)的化合物不包括:1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1-哌啶基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-甲酰胺1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1(2H)-吡啶)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-甲酰胺1-(3-氯苯基)-7-氧代-6-[4-(2-氧代-1-哌啶基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-甲酰胺1-(3-氯苯基)-7-氧代-6-[4-(2-氧代-1(2H)吡啶)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-甲酰胺1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1-哌嗪基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-甲酰胺
- 前述权利要求中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐,其特征在于:X是CH。
- 前述权利要求中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐,其特征在于:RNc选自氢和甲基。
- 前述权利要求中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐,其特征在于:RNd选自C1-3烷氧基。
- 前述权利要求中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐,其特征在于:RNc选自氢、氯和氟。
- 前述权利要求中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐,其特征在于:RNf选自氢、氯和氟。
- 一种药物组合物,其包括权利要求1-13中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐。
- 权利要求1-13中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐,或权利要求14所述的药物组合物在制备用于预防和/或治疗抑制Xa因子正性影响疾病的药物中的用途。
- 如权利要求15所述的用途,其中所述的疾病选自血栓栓塞、和弥散性血管内凝血。
- 如权利要求16所述的用途,其中所述的疾病选自心肌梗塞、心绞痛、血管成形术或主动脉冠状动脉分流术后的再阻塞和再狭窄、中风、短暂的局部发作、周围动脉闭塞性疾病、肺栓塞或深部静脉血栓形成。
- 权利要求1-13中任一项所述的式(I)的化合物,其互变异构体、其光学异构体、或其药学上可接受的盐,或权利要求14所述的药物组合物在制备用于在低出血风险的情况下预防和/或治疗抑制Xa因子正性影响疾病的药物中的用途。
- 如权利要求19所述的用途,其中所述的疾病选自血栓栓塞、和弥散性血管内凝血。
- 如权利要求20所述的用途,其中所述的疾病选自心肌梗塞、心绞痛、血管成形术或主动脉冠状动脉分流术后的再阻塞和再狭窄、中风、短暂的局部发作、周围动脉闭塞性疾病、肺栓塞或深部静脉血栓形成。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020177008810A KR102559890B1 (ko) | 2014-09-02 | 2015-09-02 | 피라졸로[3,4-c]피리딘 유도체 |
RU2017110281A RU2709810C2 (ru) | 2014-09-02 | 2015-09-02 | ПРОИЗВОДНЫЕ ПИРАЗОЛО[3,4-с]ПИРИДИНА |
CA2959987A CA2959987C (en) | 2014-09-02 | 2015-09-02 | Pyrazolo[3,4-c]pyridine compounds and their anti-thrombosis effect |
ES15838518T ES2800948T3 (es) | 2014-09-02 | 2015-09-02 | Derivados de pirazolo[3,4-c]piridina |
JP2017512022A JP6667507B2 (ja) | 2014-09-02 | 2015-09-02 | ピラゾロ[3,4−c]ピリジン誘導体 |
EP15838518.7A EP3190111B1 (en) | 2014-09-02 | 2015-09-02 | Pyrazolo[3,4-c]pyridine derivatives |
AU2015311362A AU2015311362B2 (en) | 2014-09-02 | 2015-09-02 | Pyrazolo[3,4-c]pyridine derivatives |
US15/507,956 US9975893B2 (en) | 2014-09-02 | 2015-09-02 | Pyrazolo[3,4-c]pyridine derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410442948 | 2014-09-02 | ||
CN201410442948.2 | 2014-09-02 | ||
CN201510291890.0 | 2015-06-01 | ||
CN201510291890 | 2015-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016034137A1 true WO2016034137A1 (zh) | 2016-03-10 |
Family
ID=55417562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/088898 WO2016034137A1 (zh) | 2014-09-02 | 2015-09-02 | 吡唑并[3,4-c]吡啶类衍生物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9975893B2 (zh) |
EP (1) | EP3190111B1 (zh) |
JP (1) | JP6667507B2 (zh) |
KR (1) | KR102559890B1 (zh) |
CN (1) | CN105384739B (zh) |
AU (1) | AU2015311362B2 (zh) |
CA (1) | CA2959987C (zh) |
ES (1) | ES2800948T3 (zh) |
RU (1) | RU2709810C2 (zh) |
WO (1) | WO2016034137A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9975893B2 (en) | 2014-09-02 | 2018-05-22 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Pyrazolo[3,4-c]pyridine derivatives |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111868035A (zh) * | 2018-03-15 | 2020-10-30 | 阿克萨姆股份公司 | 取代的吡唑ffa4/gpr120受体激动剂 |
CN108864084B (zh) * | 2018-06-14 | 2020-08-21 | 成都倍特药业股份有限公司 | 一组阿哌沙班有关物质及其制备方法 |
EP4215525A1 (en) | 2020-09-17 | 2023-07-26 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Piperazine derivative, preparation method therefor and use thereof |
CN116583278A (zh) * | 2020-09-18 | 2023-08-11 | 石药集团中奇制药技术(石家庄)有限公司 | 一种吡唑并[3,4-c]吡啶化合物的晶型及其制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000039131A1 (en) * | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | Nitrogen containing heterobicycles as factor xa inhibitors |
WO2003048081A2 (en) * | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
WO2006036926A2 (en) * | 2004-09-28 | 2006-04-06 | Bristol-Myers Squibb Company | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
WO2007137801A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Tetrahydro-pyrrolopyridin-, tetrahydro-pyrazolopyridin-, tetrahydro-imidazopyridin- und tetrahydro-triazolopyridin-derivate und ihre verwendung |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002065356A1 (en) | 2001-02-09 | 2002-08-22 | Onepoint Software Aps | A method of handling project material |
CA2444571A1 (en) * | 2001-04-18 | 2002-10-31 | Bristol-Myers Squibb Company | 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridin-7-ones as factor xa inhi bitors |
CH1427415H1 (de) * | 2001-09-21 | 2023-12-21 | Bristol Myers Squibb Holdings Ireland | Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer |
US7388096B2 (en) * | 2004-09-28 | 2008-06-17 | Bristol-Myers Squibb Company | Crystalline forms of a factor Xa inhibitor |
CN101068812B (zh) * | 2004-09-28 | 2010-09-29 | 布里斯托尔-迈尔斯斯奎布公司 | 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮的有效合成 |
TW200622494A (en) * | 2004-09-30 | 2006-07-01 | Kyowa Hakko Chemical Co Ltd | Photoresist composition for positive liquid crystal device |
EP2638007A2 (en) * | 2010-11-11 | 2013-09-18 | Redx Pharma Limited | Drug derivatives |
WO2013119328A1 (en) * | 2012-02-07 | 2013-08-15 | Assia Chemical Industries Ltd. | Solid state forms of apixaban |
CN104650072B (zh) * | 2013-11-18 | 2016-03-16 | 成都苑东生物制药股份有限公司 | 一种吡啶类衍生物 |
CA2959987C (en) | 2014-09-02 | 2023-05-09 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Pyrazolo[3,4-c]pyridine compounds and their anti-thrombosis effect |
CN104311556B (zh) * | 2014-09-19 | 2016-06-01 | 广东东阳光药业有限公司 | 含有环氧烷基取代基的吡唑并哌啶酮类化合物及其组合物及用途 |
-
2015
- 2015-09-02 CA CA2959987A patent/CA2959987C/en active Active
- 2015-09-02 WO PCT/CN2015/088898 patent/WO2016034137A1/zh active Application Filing
- 2015-09-02 EP EP15838518.7A patent/EP3190111B1/en active Active
- 2015-09-02 AU AU2015311362A patent/AU2015311362B2/en active Active
- 2015-09-02 CN CN201510555645.6A patent/CN105384739B/zh active Active
- 2015-09-02 RU RU2017110281A patent/RU2709810C2/ru active
- 2015-09-02 KR KR1020177008810A patent/KR102559890B1/ko active IP Right Grant
- 2015-09-02 US US15/507,956 patent/US9975893B2/en active Active
- 2015-09-02 JP JP2017512022A patent/JP6667507B2/ja active Active
- 2015-09-02 ES ES15838518T patent/ES2800948T3/es active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000039131A1 (en) * | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | Nitrogen containing heterobicycles as factor xa inhibitors |
WO2003048081A2 (en) * | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
WO2006036926A2 (en) * | 2004-09-28 | 2006-04-06 | Bristol-Myers Squibb Company | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
WO2007137801A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Tetrahydro-pyrrolopyridin-, tetrahydro-pyrazolopyridin-, tetrahydro-imidazopyridin- und tetrahydro-triazolopyridin-derivate und ihre verwendung |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9975893B2 (en) | 2014-09-02 | 2018-05-22 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Pyrazolo[3,4-c]pyridine derivatives |
Also Published As
Publication number | Publication date |
---|---|
KR20170054424A (ko) | 2017-05-17 |
EP3190111B1 (en) | 2020-05-06 |
CN105384739B (zh) | 2020-03-20 |
EP3190111A4 (en) | 2018-02-07 |
AU2015311362B2 (en) | 2020-04-30 |
RU2017110281A (ru) | 2018-10-03 |
US20170291896A1 (en) | 2017-10-12 |
AU2015311362A1 (en) | 2017-04-13 |
JP2017530104A (ja) | 2017-10-12 |
CN105384739A (zh) | 2016-03-09 |
US9975893B2 (en) | 2018-05-22 |
CA2959987A1 (en) | 2016-03-10 |
KR102559890B1 (ko) | 2023-07-27 |
ES2800948T3 (es) | 2021-01-05 |
RU2709810C2 (ru) | 2019-12-23 |
CA2959987C (en) | 2023-05-09 |
JP6667507B2 (ja) | 2020-03-18 |
RU2017110281A3 (zh) | 2019-03-07 |
EP3190111A1 (en) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6220786B2 (ja) | 1−(シクロアルキルカルボニル)プロリン誘導体 | |
JP4445504B2 (ja) | Dpp−iv阻害剤としてのヘキサヒドロピリドイソキノリン | |
JP2024514703A (ja) | ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 | |
WO2016034137A1 (zh) | 吡唑并[3,4-c]吡啶类衍生物 | |
RU2672582C2 (ru) | Бициклические ингибиторы | |
WO2004048379A1 (ja) | キサンチン化合物 | |
JP2009522295A (ja) | 置換ビス−アミドメタロプロテアーゼ阻害剤 | |
JP2021502358A (ja) | アルファvインテグリン阻害剤としてのピロロピラジン誘導体 | |
JP6860237B2 (ja) | インドールアミン2,3−ジオキシゲナーゼ阻害剤及び適用 | |
AU2015215335A1 (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising same and use thereof | |
JP2000063363A (ja) | 新規なトリアゾール誘導体 | |
JP3853389B2 (ja) | 新規の3−フェニルスルホニル−3,7−ジアザビシクロ[3,3,1]ノナン−化合物、その製法及び抗不整脈剤 | |
CA2841897A1 (en) | Novel compound having parp inhibitory activity | |
JPH08253453A (ja) | フエニルシクロヘキシルカルボキシアミド類の利用 | |
JP5959617B2 (ja) | オタミキサバンの安息香酸塩 | |
WO2022166923A1 (zh) | 苯基二氢嘧啶类化合物及其应用 | |
TW201720433A (zh) | 治療及/或預防纖維性疾病之胺基萘醌化合物 | |
JP2010189275A (ja) | ナフタレン誘導体 | |
WO2015051713A1 (zh) | 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用 | |
KR102388926B1 (ko) | 5-클로로-티오펜-2-카복실산 [(s)-2-[메틸-3-(2-옥소-피롤리딘-1-일)-벤젠설포닐아미노]-3-(4-메틸 피페라진-1-일)-3-옥소-프로필]아미드의 타르트레이트 염 | |
CN114671878B (zh) | 取代的含氮双环化合物及其用途 | |
WO2022184111A1 (zh) | 与tau蛋白结合的小分子化合物 | |
JPH05117280A (ja) | アミノ酸置換チアゼトキノリン−3−カルボン酸誘導体 | |
CN118146197A (zh) | 炔类化合物及其制备方法、药物组合物与应用 | |
CN117263944A (zh) | 泛素特异性蛋白酶1抑制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15838518 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2017512022 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15507956 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2959987 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015838518 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015838518 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20177008810 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017110281 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015311362 Country of ref document: AU Date of ref document: 20150902 Kind code of ref document: A |